Ruxolitinib May Improve Control vs. Best Available Treatment in Steroid Refractory/Dependent cGVHD
After 3 years, ruxolitinib provided improved control for steroid refractory or dependent chronic graft-versus-host disease when compared with best available treatment.
Finley-Oliver Talks Talquetamab and Other Later Line Multiple Myeloma Therapies
Beth Finley-Oliver, MSN, ARNP, AGNP-BC, recaps part of her presentation from the 2023 JADPRO meeting about caring for patients with high-risk multiple myeloma.
Tisagenlecleucel Induces Durable Responses in R/R Follicular Lymphoma
The median overall survival among those treated with tisagenlecleucel was not reached, and the 36-month overall survival rate was 82%.
Laura Zitella Discusses the Growing Arsenal of Bispecific Antibodies in DLBCL
Laura Zitella, MS, RN, ACNP-BC, AOCN, discusses how newly approved bispecific antibodies are expanding third-line treatment options for patients with diffuse large B-cell lymphoma.
Bridging Therapy Responses May Outcomes With Axi-Cel Administration in Real-World Setting
High disease burden may be associated with more bridging therapy use and contribute to worse outcomes, according to investigators.
Finley-Oliver Weighs in on Caring for Heavily Pretreated Patients With High-Risk Multiple Myeloma
Beth Finley-Oliver, MSN, ARNP, AGNP-BC, discusses the growing number of new therapies for patients with relapsed or refractory multiple myeloma.
Frontline Olaparib Plus Abiraterone Provides Consistent Clinical Benefit in HRR-Mutated mCRPC
Assessing Subsequent Therapies in mHSPC Confirms OS Benefit From Darolutamide
Long-term Regorafenib Remission in mCRC May Be Linked to ECOG Score, Less Advanced Disease
Abiraterone Plus Prednisone, Apalutamide Improves Prostate Cancer Outcomes Without Impacting HRQoL
2 Commerce Drive Cranbury, NJ 08512